|
1
|
Greenlee RT, Murray T, Bolden S and Wingo
PA: Cancer statistics, 2000. CA Cancer J Clin. 50:7–33. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ward E, Brawley O and Jemal A:
Cancer statistics, 2011: The impact of eliminating socioeconomic
and racial disparities on premature cancer deaths. CA Cancer J
Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karantanos T, Corn PG and Thompson TC:
Prostate cancer progression after androgen deprivation therapy:
Mechanisms of castrate resistance and novel therapeutic approaches.
Oncogene. 32:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Marques RB, Dits NF, Erkens-Schulze S, van
Weerden WM and Jenster G: Bypass mechanisms of the androgen
receptor pathway in therapy-resistant prostate cancer cell models.
PLoS One. 5:e135002010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shakibaei M, Mobasheri A, Lueders C, Busch
F, Shayan P and Goel A: Curcumin enhances the effect of
chemotherapy against colorectal cancer cells by inhibition of NF-κB
and Src protein kinase signaling pathways. PLoS One. 8:e572182013.
View Article : Google Scholar
|
|
6
|
Sadzuka Y, Nagamine M, Toyooka T, Ibuki Y
and Sonobe T: Beneficial effects of curcumin on antitumor activity
and adverse reactions of doxorubicin. Int J Pharm. 432:42–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chuang SE, Kuo ML, Hsu CH, Chen CR, Lin
JK, Lai GM, Hsieh CY and Cheng AL: Curcumin-containing diet
inhibits diethylnitrosamine-induced murine hepatocarcinogenesis.
Carcinogenesis. 21:331–335. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Strimpakos AS and Sharma RA: Curcumin:
Preventive and therapeutic properties in laboratory studies and
clinical trials. Antioxid Redox Signal. 10:511–545. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khor TO, Keum YS, Lin W, Kim JH, Hu R,
Shen G, Xu C, Gopalakrishnan A, Reddy B, Zheng X, et al: Combined
inhibitory effects of curcumin and phenethyl isothiocyanate on the
growth of human PC-3 prostate xenografts in immunodeficient mice.
Cancer Res. 66:613–621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dorai T, Gehani N and Katz A: Therapeutic
potential of curcumin in human prostate cancer-I. curcumin induces
apoptosis in both androgen-dependent and androgen-independent
prostate cancer cells. Prostate Cancer Prostatic Dis. 3:84–93.
2000. View Article : Google Scholar
|
|
11
|
Anand P, Kunnumakkara AB, Newman RA and
Aggarwal BB: Bioavailability of curcumin: Problems and promises.
Mol Pharm. 4:807–818. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adams BK, Cai J, Armstrong J, Herold M, Lu
YJ, Sun A, Snyder JP, Liotta DC, Jones DP and Shoji M: EF24, a
novel synthetic curcumin analog, induces apoptosis in cancer cells
via a redox-dependent mechanism. Anticancer Drugs. 16:263–275.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei X, Zhou D, Wang H, Ding N, Cui XX,
Wang H, Verano M, Zhang K, Conney AH, Zheng X, et al: Effects of
pyridine analogs of curcumin on growth, apoptosis and NF-κB
activity in prostate cancer PC-3 cells. Anticancer Res.
33:1343–1350. 2013.PubMed/NCBI
|
|
14
|
Yadav B, Taurin S, Rosengren RJ,
Schumacher M, Diederich M, Somers-Edgar TJ and Larsen L: Synthesis
and cytotoxic potential of heterocyclic cyclohexanone analogues of
curcumin. Bioorg Med Chem. 18:6701–6707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yadav B, Taurin S, Larsen L and Rosengren
RJ: RL66 a second-generation curcumin analog has potent in vivo and
in vitro anticancer activity in ER-negative breast cancer models.
Int J Oncol. 41:1723–1732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yadav B, Taurin S, Larsen L and Rosengren
RJ: RL71, a second-generation curcumin analog, induces apoptosis
and downregulates Akt in ER-negative breast cancer cells. Int J
Oncol. 41:1119–1127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Somers-Edgar TJ, Taurin S, Larsen L,
Chandramouli A, Nelson MA and Rosengren RJ: Mechanisms for the
activity of heterocyclic cyclohexanone curcumin derivatives in
estrogen receptor negative human breast cancer cell lines. Invest
New Drugs. 29:87–97. 2011. View Article : Google Scholar
|
|
18
|
Stuart EC, Jarvis RM and Rosengren RJ: In
vitro mechanism of action for the cytotoxicity elicited by the
combination of epigallocatechin gallate and raloxifene in
MDA-MB-231 cells. Oncol Rep. 24:779–785. 2010.PubMed/NCBI
|
|
19
|
Beresford SA, Davies MA, Gallick GE and
Donato NJ: Differential effects of
phosphatidylinositol-3/Akt-kinase inhibition on apoptotic
sensitization to cytokines in LNCaP and PCc-3 prostate cancer
cells. J Interferon Cytokine Res. 21:313–322. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Samaan N, Zhong Q, Fernandez J, Chen G,
Hussain AM, Zheng S, Wang G and Chen QH: Design, synthesis, and
evaluation of novel heteroaromatic analogs of curcumin as
anti-cancer agents. Eur J Med Chem. 75:123–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mazumder A, Gould M, Taurin S, Nicholson H
and Rosengren R: Raloxifene potentiates the cytotoxicity induced by
RL91, a second generation curcumin analog, in PC3 prostate cancer
cells. Toxicologist. 132:1462013.
|
|
22
|
Zhang X, Chen M, Zou P, Kanchana K, Weng
Q, Chen W, Zhong P, Ji J, Zhou H, He L, et al: Curcumin analog WZ35
induced cell death via ROS-dependent ER stress and G2/M cell cycle
arrest in human prostate cancer cells. BMC Cancer. 15:8662015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin L, Hutzen B, Ball S, Foust E, Sobo M,
Deangelis S, Pandit B, Friedman L, Li C, Li PK, et al: New curcumin
analogues exhibit enhanced growth-suppressive activity and inhibit
AKT and signal transducer and activator of transcription 3
phosphorylation in breast and prostate cancer cells. Cancer Sci.
100:1719–1727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chiu TL and Su CC: Curcumin inhibits
proliferation and migration by increasing the Bax to Bcl-2 ratio
and decreasing NF-kappaBp65 expression in breast cancer MDA-MB-231
cells. Int J Mol Med. 23:469–475. 2009.PubMed/NCBI
|
|
25
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khan N, Adhami VM and Mukhtar H: Apoptosis
by dietary agents for prevention and treatment of prostate cancer.
Endocr Relat Cancer. 17:R39–R52. 2010. View Article : Google Scholar
|
|
27
|
Mandalapu D, Saini KS, Gupta S, Sharma V,
Yaseen Malik M, Chaturvedi S, Bala V, Hamidullah, Thakur S,
Maikhuri JP, et al: Synthesis and biological evaluation of some
novel triazole hybrids of curcumin mimics and their selective
anticancer activity against breast and prostate cancer cell lines.
Bioorg Med Chem Lett. 26:4223–4232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei X, Du ZY, Cui XX, Verano M, Mo RQ,
Tang ZK, Conney AH, Zheng X and Zhang K: Effects of cyclohexanone
analogues of curcumin on growth, apoptosis and NF-κB activity in
PC-3 human prostate cancer cells. Oncol Lett. 4:279–284.
2012.PubMed/NCBI
|
|
29
|
Oliver KM, Taylor CT and Cummins EP:
Hypoxia. Regulation of NFkappaB signalling during inflammation: The
role of hydroxylases. Arthritis Res Ther. 11:2152009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Walmsley SR, Print C, Farahi N,
Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A, Condliffe AM,
Cowburn AS, Johnson N, et al: Hypoxia-induced neutrophil survival
is mediated by HIF-1α-dependent NF-kappaB activity. J Exp Med.
201:105–115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maxwell PJ, Gallagher R, Seaton A, Wilson
C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG
and Waugh DJ: HIF-1 and NF-kappaB-mediated upregulation of CXCR1
and CXCR2 expression promotes cell survival in hypoxic prostate
cancer cells. Oncogene. 26:7333–7345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Suh J, Payvandi F, Edelstein LC, Amenta
PS, Zong WX, Gélinas C and Rabson AB: Mechanisms of constitutive
NF-kappaB activation in human prostate cancer cells. Prostate.
52:183–200. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Abdulghani J, Gu L, Dagvadorj A, Lutz J,
Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T,
et al: Stat3 promotes metastatic progression of prostate cancer. Am
J Pathol. 172:1717–1728. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lindholm PF, Bub J, Kaul S, Shidham VB and
Kajdacsy-Balla A: The role of constitutive NF-kappaB activity in
PC-3 human prostate cancer cell invasive behavior. Clin Exp
Metastasis. 18:471–479. 2000. View Article : Google Scholar
|
|
35
|
Lessard L, Bégin LR, Gleave ME, Mes-Masson
AM and Saad F: Nuclear localisation of nuclear factor-kappaB
transcription factors in prostate cancer: An immunohistochemical
study. Br J Cancer. 93:1019–1023. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Domingo-Domenech J, Oliva C, Rovira A,
Codony-Servat J, Bosch M, Filella X, Montagut C, Tapia M, Campás C,
Dang L, et al: Interleukin 6, a nuclear factor-kappaB target,
predicts resistance to docetaxel in hormone-independent prostate
cancer and nuclear factor-kappaB inhibition by PS-1145 enhances
docetaxel antitumor activity. Clin Cancer Res. 12:5578–5586. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ross JS, Kallakury BV, Sheehan CE, Fisher
HA, Kaufman RP Jr, Kaur P, Gray K and Stringer B: Expression of
nuclear factor-κ B and IκBα proteins in prostatic adenocarcinomas:
Correlation of nuclear factor-κB immunoreactivity with disease
recurrence. Clin Cancer Res. 10:2466–2472. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chakraborty M, Qiu SG, Vasudevan KM and
Rangnekar VM: Par-4 drives trafficking and activation of Fas and
Fasl to induce prostate cancer cell apoptosis and tumor regression.
Cancer Res. 61:7255–7263. 2001.PubMed/NCBI
|
|
39
|
Jin R, Sterling JA, Edwards JR, DeGraff
DJ, Lee C, Park SI and Matusik RJ: Activation of NF-kappa B
signaling promotes growth of prostate cancer cells in bone. PLoS
One. 8:e609832013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Huang S, Pettaway CA, Uehara H, Bucana CD
and Fidler IJ: Blockade of NF-kappaB activity in human prostate
cancer cells is associated with suppression of angiogenesis,
invasion, and metastasis. Oncogene. 20:4188–4197. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang CH, Yue J, Sims M and Pfeffer LM: The
curcumin analog EF24 targets NF-κB and miRNA-21, and has potent
anticancer activity in vitro and in vivo. PLoS One. 8:e711302013.
View Article : Google Scholar
|
|
42
|
Olivera A, Moore TW, Hu F, Brown AP, Sun
A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, et al:
Inhibition of the NF-κB signaling pathway by the curcumin analog,
3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31):
Anti-inflammatory and anti-cancer properties. Int Immunopharmacol.
12:368–377. 2012. View Article : Google Scholar
|
|
43
|
Jorissen RN, Walker F, Pouliot N, Garrett
TP, Ward CW and Burgess AW: Epidermal growth factor receptor:
Mechanisms of activation and signalling. Exp Cell Res. 284:31–53.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nicholson RI, Gee JM and Harper ME: EGFR
and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Di Lorenzo G, Tortora G, D'Armiento FP, De
Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De
Placido S, Catalano G, et al: Expression of epidermal growth factor
receptor correlates with disease relapse and progression to
androgen-independence in human prostate cancer. Clin Cancer Res.
8:3438–3444. 2002.PubMed/NCBI
|
|
46
|
Kim JH, Xu C, Keum YS, Reddy B, Conney A
and Kong AN: Inhibition of EGFR signaling in human prostate cancer
PC-3 cells by combination treatment with β-phenylethyl
isothiocyanate and curcumin. Carcinogenesis. 27:475–482. 2006.
View Article : Google Scholar
|
|
47
|
Shinde SR and Maddika S: PTEN modulates
EGFR late endocytic trafficking and degradation by
dephosphorylating Rab7. Nat Commun. 7:106892016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rush JS, Quinalty LM, Engelman L, Sherry
DM and Ceresa BP: Endosomal accumulation of the activated epidermal
growth factor receptor (EGFR) induces apoptosis. J Biol Chem.
287:712–722. 2012. View Article : Google Scholar :
|
|
49
|
Dillon RL, White DE and Muller WJ: The
phosphatidyl inositol 3-kinase signaling network: Implications for
human breast cancer. Oncogene. 26:1338–1345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
51
|
Graff JR, Konicek BW, McNulty AM, Wang Z,
Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, et al:
Increased AKT activity contributes to prostate cancer progression
by dramatically accelerating prostate tumor growth and diminishing
p27Kip1 expression. J Biol Chem. 275:24500–24505. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shimizu Y, Segawa T, Inoue T, Shiraishi T,
Yoshida T, Toda Y, Yamada T, Kinukawa N, Terada N, Kobayashi T, et
al: Increased Akt and phosphorylated Akt expression are associated
with malignant biological features of prostate cancer in Japanese
men. BJU Int. 100:685–690. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: Inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ayala G, Thompson T, Yang G, Frolov A, Li
R, Scardino P, Ohori M, Wheeler T and Harper W: High levels of
phosphorylated form of Akt-1 in prostate cancer and non-neoplastic
prostate tissues are strong predictors of biochemical recurrence.
Clin Cancer Res. 10:6572–6578. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kreisberg JI, Malik SN, Prihoda TJ,
Bedolla RG, Troyer DA, Kreisberg S and Ghosh PM: Phosphorylation of
Akt (Ser473) is an excellent predictor of poor clinical outcome in
prostate cancer. Cancer Res. 64:5232–5236. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Mimeault M, Johansson SL and Batra SK:
Pathobiological implications of the expression of EGFR, pAkt, NF-κB
and MIC-1 in prostate cancer stem cells and their progenies. PLoS
One. 7:e319192012. View Article : Google Scholar
|
|
57
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
58
|
Pópulo H, Lopes JM and Soares P: The mTOR
signalling pathway in human cancer. Int J Mol Sci. 13:1886–1918.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kremer CL, Klein RR, Mendelson J, Browne
W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA and Nagle
RB: Expression of mTOR signaling pathway markers in prostate cancer
progression. Prostate. 66:1203–1212. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liu G, Zhang Y, Bode AM, Ma WY and Dong Z:
Phosphorylation of 4E-BP1 is mediated by the p38/MSK1 pathway in
response to UVB irradiation. J Biol Chem. 277:8810–8816. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Haystead TA, Haystead CM, Hu C, Lin TA and
Lawrence JC Jr: Phosphorylation of PHAS-I by mitogen-activated
protein (MAP) kinase. Identification of a site phosphorylated by
MAP kinase in vitro and in response to insulin in rat adipocytes. J
Biol Chem. 269:23185–23191. 1994.PubMed/NCBI
|
